216 related articles for article (PubMed ID: 27879973)
21. Prognostic and predictive values of immune infiltrate in patients with head and neck squamous cell carcinoma.
Zhang XM; Song LJ; Shen J; Yue H; Han YQ; Yang CL; Liu SY; Deng JW; Jiang Y; Fu GH; Shen WW
Hum Pathol; 2018 Dec; 82():104-112. PubMed ID: 30036594
[TBL] [Abstract][Full Text] [Related]
22. Infiltrating memory/senescent T cell ratio predicts extrahepatic metastasis of hepatocellular carcinoma.
Gao Q; Zhou J; Wang XY; Qiu SJ; Song K; Huang XW; Sun J; Shi YH; Li BZ; Xiao YS; Fan J
Ann Surg Oncol; 2012 Feb; 19(2):455-66. PubMed ID: 21792513
[TBL] [Abstract][Full Text] [Related]
23. Associations between infiltrating lymphocyte subsets and hepatocellular carcinoma.
Guo CL; Yang HC; Yang XH; Cheng W; Dong TX; Zhu WJ; Xu Z; Zhao L
Asian Pac J Cancer Prev; 2012; 13(11):5909-13. PubMed ID: 23317279
[TBL] [Abstract][Full Text] [Related]
24. Reliability of a single-region sample to evaluate tumor immune microenvironment in hepatocellular carcinoma.
Shen YC; Hsu CL; Jeng YM; Ho MC; Ho CM; Yeh CP; Yeh CY; Hsu MC; Hu RH; Cheng AL
J Hepatol; 2020 Mar; 72(3):489-497. PubMed ID: 31634533
[TBL] [Abstract][Full Text] [Related]
25. Tumor-infiltrating CD45RO
Hu G; Wang S
Sci Rep; 2017 Sep; 7(1):10376. PubMed ID: 28871164
[TBL] [Abstract][Full Text] [Related]
26. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages.
Vieira T; Antoine M; Hamard C; Fallet V; Duruisseaux M; Rabbe N; Rodenas A; Cadranel J; Wislez M
Lung Cancer; 2016 Aug; 98():51-58. PubMed ID: 27393506
[TBL] [Abstract][Full Text] [Related]
27. Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma.
Tian MX; Liu WR; Wang H; Zhou YF; Jin L; Jiang XF; Tao CY; Tang Z; Zhou PY; Fang Y; Qu WF; Ding ZB; Peng YF; Dai Z; Qiu SJ; Zhou J; Lau WY; Fan J; Shi YH
BMC Med; 2019 Jun; 17(1):106. PubMed ID: 31164128
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of tumor-infiltrating FOXP3+ regulatory T cells in patients with hepatocellular carcinoma.
Sasaki A; Tanaka F; Mimori K; Inoue H; Kai S; Shibata K; Ohta M; Kitano S; Mori M
Eur J Surg Oncol; 2008 Feb; 34(2):173-9. PubMed ID: 17928188
[TBL] [Abstract][Full Text] [Related]
29. Existence of intratumoral tertiary lymphoid structures is associated with immune cells infiltration and predicts better prognosis in early-stage hepatocellular carcinoma.
Li H; Wang J; Liu H; Lan T; Xu L; Wang G; Yuan K; Wu H
Aging (Albany NY); 2020 Feb; 12(4):3451-3472. PubMed ID: 32087064
[TBL] [Abstract][Full Text] [Related]
30. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.
Pagès F; Mlecnik B; Marliot F; Bindea G; Ou FS; Bifulco C; Lugli A; Zlobec I; Rau TT; Berger MD; Nagtegaal ID; Vink-Börger E; Hartmann A; Geppert C; Kolwelter J; Merkel S; Grützmann R; Van den Eynde M; Jouret-Mourin A; Kartheuser A; Léonard D; Remue C; Wang JY; Bavi P; Roehrl MHA; Ohashi PS; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Masucci GV; Andersson EK; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Nemejcova K; Botti G; Tatangelo F; Delrio P; Ciliberto G; Maio M; Laghi L; Grizzi F; Fredriksen T; Buttard B; Angelova M; Vasaturo A; Maby P; Church SE; Angell HK; Lafontaine L; Bruni D; El Sissy C; Haicheur N; Kirilovsky A; Berger A; Lagorce C; Meyers JP; Paustian C; Feng Z; Ballesteros-Merino C; Dijkstra J; van de Water C; van Lent-van Vliet S; Knijn N; Mușină AM; Scripcariu DV; Popivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Torigoe T; Sato N; Furuhata T; Takemasa I; Itoh K; Patel PS; Vora HH; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Kawakami Y; Marincola FM; Ascierto PA; Sargent DJ; Fox BA; Galon J
Lancet; 2018 May; 391(10135):2128-2139. PubMed ID: 29754777
[TBL] [Abstract][Full Text] [Related]
31. Role of Foxp3-positive tumor-infiltrating lymphocytes in the histologic features and clinical outcomes of hepatocellular carcinoma.
Mathai AM; Kapadia MJ; Alexander J; Kernochan LE; Swanson PE; Yeh MM
Am J Surg Pathol; 2012 Jul; 36(7):980-6. PubMed ID: 22446942
[TBL] [Abstract][Full Text] [Related]
32. CD45RO(+) Memory T Lymphocytes--a Candidate Marker for TNM-Immunoscore in Squamous Non-Small Cell Lung Cancer.
Paulsen EE; Kilvaer T; Khanehkenari MR; Maurseth RJ; Al-Saad S; Hald SM; Al-Shibli K; Andersen S; Richardsen E; Busund LT; Bremnes R; Donnem T
Neoplasia; 2015 Nov; 17(11):839-48. PubMed ID: 26678911
[TBL] [Abstract][Full Text] [Related]
33. Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases.
Uruga H; Bozkurtlar E; Huynh TG; Muzikansky A; Goto Y; Gomez-Caraballo M; Hata AN; Gainor JF; Mark EJ; Engelman JA; Lanuti MD; Mino-Kenudson M
J Thorac Oncol; 2017 Mar; 12(3):458-466. PubMed ID: 27815126
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value and clinical relevance of the 6th Edition 2002 American Joint Committee on Cancer staging system in patients with resectable hepatocellular carcinoma.
Lei HJ; Chau GY; Lui WY; Tsay SH; King KL; Loong CC; Wu CW
J Am Coll Surg; 2006 Oct; 203(4):426-35. PubMed ID: 17000385
[TBL] [Abstract][Full Text] [Related]
35. The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma.
Agdashian D; ElGindi M; Xie C; Sandhu M; Pratt D; Kleiner DE; Figg WD; Rytlewski JA; Sanders C; Yusko EC; Wood B; Venzon D; Brar G; Duffy AG; Greten TF; Korangy F
Cancer Immunol Immunother; 2019 Apr; 68(4):599-608. PubMed ID: 30688989
[TBL] [Abstract][Full Text] [Related]
36. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
37. Liver-infiltrating CD8(+) lymphocytes as prognostic factor for tumour recurrence in hepatitis C virus-related hepatocellular carcinoma.
Ramzan M; Sturm N; Decaens T; Bioulac-Sage P; Bancel B; Merle P; Tran Van Nhieu J; Slama R; Letoublon C; Zarski JP; Jouvin-Marche E; Marche PN; Leroy V
Liver Int; 2016 Mar; 36(3):434-44. PubMed ID: 26215124
[TBL] [Abstract][Full Text] [Related]
38. Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer.
Donnem T; Kilvaer TK; Andersen S; Richardsen E; Paulsen EE; Hald SM; Al-Saad S; Brustugun OT; Helland A; Lund-Iversen M; Solberg S; Gronberg BH; Wahl SG; Helgeland L; Fløtten O; Pohl M; Al-Shibli K; Sandanger TM; Pezzella F; Busund LT; Bremnes RM
Ann Oncol; 2016 Feb; 27(2):225-32. PubMed ID: 26578726
[TBL] [Abstract][Full Text] [Related]
39. Regulatory T cells and their prognostic value in hepatopancreatobiliary tumours.
Ozgur HH; Ercetin AP; Eliyatkin N; Seren A; Kupelioglu A; Ortac R; Diniz G; Aktas S
Hepatogastroenterology; 2014 Oct; 61(135):1847-51. PubMed ID: 25713876
[TBL] [Abstract][Full Text] [Related]
40. Prognostic evaluation of the new American Joint Committee on Cancer/International Union Against Cancer staging system for hepatocellular carcinoma: analysis of 112 cirrhotic patients resected for hepatocellular carcinoma.
Ramacciato G; Mercantini P; Cautero N; Corigliano N; Di Benedetto F; Quintini C; Ercolani G; Varotti G; Ziparo V; Pinna AD
Ann Surg Oncol; 2005 Apr; 12(4):289-97. PubMed ID: 15827681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
